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ABSTRACT
Objectives: Mycoplasma pneumoniae is an atypical pathogen, which is one of the major causes of 
lower respiratory tract infections (LRTIs) worldwide. This study was performed to determine the 
role of M. pneumoniae in acute LRTIs in children, who were referred to main pediatric hospitals in 
Shiraz, Iran, with the diagnosis of LRTI. Polymerase chain reaction method on a throat-swab speci-
men was utilized to detect M. pneumoniae. Results: One hundred patients with acute LRTIs were 
investigated in this study. There were 10 positive PCR for M. pneumoniae (10%), including 6 of 62 
hospitalized patients and 4 of 38 outpatients. All patients with LRTIs due to M. pneumoniae had 
cough. Fever, flu like symptoms, dyspnea, pulmonary rales, wheezing, and conjunctivitis were other 
common signs and symptoms. Conclusions: The percentage of cases with M. pneumoniae infection 
in our population is similar to the reported in other parts of Asia. Precise and early detection of path-
ogen and appropriate antibiotic therapy are the key points in management of patients with LRTIs.
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INTRODUCTION
Lower respiratory tract infections (LRTIs) con-
tinue to be a common cause of morbidity and 
mortality, especially in the pediatric age group,1,2 
contributing to about 1.9 million children’s 
deaths yearly.3 Determination of the putative 
pathogens is one of the main difficulties in LR-
TIs, as the diagnostic tests of respiratory samples 
are not sensitive enough to identify the causative 
microorganisms in most patients.4,5 It is estimat-
ed that antigen screening, culture and serologi-
cal methods can be helpful in only one third of 
the cases.6 Therefore therapy is usually empiric 
in most cases.7,8
Atypical pathogens, particularly Myco-
plasma pneumoniae, are major causes of acute 
LRTIs. Although M. pneumoniae usually causes 
pneumonia and bronchitis, other clinical mani-
festations such as rhinitis, pharyngitis, sinusi-
tis and otitis media can also be seen.9,10 There 
are some reports indicating significant role of 
M. pneumoniae as cause of LRTIs in children of 
all ages,11,12 which underscores the importance of 
specific pathogen diagnosis, as the use of proper 
antibiotics, such as macrolides, can significantly 
reduce duration of the illnesses.13,14
Unfortunately, as result of the difficulty to 
detect M. pneumoniae due to insensitive culture 
and time-consuming and impractical in clini-
cal practice, specific etiologic diagnoses have 
remained unknown in the majority of cases.15 
Several methods were utilized for detection 
of this pathogen, including cold agglutination 
test,16 serological methods (Mycoplasma IgM 
antibody, complement fixation, ELISA)17,18 and 
microparticle agglutination test.19 However, 
there were a number of limitations with these 
methods, especially regarding sensitivity and 
specificity. Therefore polymerase chain reac-
tion (PCR) is suggested as of the most practical 
typing method for rapid and sensitive detec-
tion of M. pneumoniae in throat swabs.20,21 The 
PCR method could provide rapid diagnosis of 
M. pneumoniae infection, especially in younger 
children, and is a valuable method considering 
epidemiological, clinical, economic aspects in 
addition to turnaround time of results.22-24 The 
sensitivity and specificity of the PCR method 
has been estimated about 70% and 80%, re-
spectively.24
This study was performed to determine the 
role of M. pneumoniae in acute LRTIs in chil-
dren, with use of PCR analysis.




This prospective study was performed in 2006 on pedi-
atric patients, who were referred to Namazee and Dast-
gheib Hospitals (Shiraz, Iran) because of acute lower 
respiratory tract infections. This study was approved by 
Ethics Committee of the Hospital, Shiraz University of 
Medical Sciences. Written informed consent was taken 
from the parents of enrolled patients.
Patients enrollment
One hundred children (64 boys and 36 girls) were in-
cluded in this study. Demographic data and patients’ 
history were documented in the standardized ques-
tionnaire, designed for this study. All symptoms and 
detected signs in the physical examination, including 
cough, flu-like symptoms, dyspnea, pulmonary rales, 
wheezing, and conjunctivitis were also recorded. Ini-
tial laboratory investigations, including complete cell 
blood count and chest X-ray, were done before throat-
swab sampling. The patients with the following crite-
ria were enrolled in this study: respiratory symptoms 
associated with abnormal chest X-ray suggestive of 
pneumonia, respiratory distress, and presence of rales 
in lung examination. Fever was defined as body tem-
perature higher than 37.8°C.
Exclusion criteria
Patients with chronic respiratory problems, such as 
asthma and cystic fibrosis, and other chronic diseases, 
such as malignant disease, tuberculosis and autoim-
mune diseases, were excluded from this study. Those 
who had history of blood transfusions or immunosup-
pressive therapy were also excluded. Enrolled patients 
were not receiving antibiotics during the 72 hours be-
fore sampling.
PCR method
The polymerase chain reaction (PCR) method on a 
throat-swab specimen was utilized to detect M. pneu-
moniae. Although all the patients were prescribed a 10-
day course of macrolides (erythromycin or azithromy-
cin at the recommended dose), throat-swab specimens 
were taken at the first day prior to antibiotic therapy. 
The samples were transported in PPLO broth to the 
microbiology laboratory and were incubated at 37°C 
for a few hours after removing the swabs. The cultures 
were centrifuged at 1,000 g for 5 minutes. The super-
natant then was collected in a sterile 1 mL Eppendorf 
tube and centrifuged at 20,000 g for 20 minutes. After 
decanting the supernatant the pellet was suspended in 
20 µL of sterile Mili-Q water and boiled for 10 minutes. 
The latter was then used as DNA template in PCR reac-
tions which were performed by the M. pneumoniae PCR 
kit (Genekam Biotechnology AG, Germany), based on 
the protocol. The negative and positive controls pro-
vided in the kit were used in each assay. DNA fragments 
were visualized on 1% agarose gel by electrophoresis.
Statistical analysis
Epi Info 6 program (version 6.2, World Health Organi-
zation, Geneva, Switzerland) was used for statistical 
analyses. Association between categorical variables were 
assessed by Chi-square or Fisher’s exact test. P-value of 
less than 0.05 was considered statistically significant.
RESULTS
Characteristics of patients 
One hundred patients with acute LRTIs (64 male and 36 
female), including 62 hospitalized and 38 outpatients, 
were investigated in this study. Patients’ ages ranged 
from 6 months to 17 years.
Positive PCR patients
Among 100 investigated patients, PCR for M. pneumoni-
ae turned out positive in 10 (10%) patients, being 5 boys 
(7,8%) and 5 girls (13,8%) [p = 0.48]. M. pneumoniae 
positivity rates among hospitalized patients (9.5%) and 
outpatients (10.5%) were similar (p = 0.57).
Seasonal variations
Half of the identified M. pneumoniae cases were referred 
during the autumn season, while only 3 cases occurred dur-
ing the winter and 2 cases in the spring. No M. pneumo-
niae was detected during the summer season.
Clinical manifestations
All patients with acute LRTI due to M. pneumoniae 
complained of cough lasting for a mean of 9.5 days, com-
pared to a mean duration of 7 days among PCR nega- 
tive patients (p = 0.35). Although 8 out of 10 patients 
with positive PCR had fever at the time of admission, 
and all but one had low-grade fever. Half of the cases 
presented with productive cough, while the remaining 
half had dry cough, irrespective of being positive and 
negative PCR for M. pneumoniae. Flu-like symptoms 
were present in 40% of the patients with M. pneumoni-
ae, which was lower than the 63.3% seen in the negative 
patients. However, this difference was not significant 
(p = 0.18). In contrast, dyspnea was more common among 
PCR-positive patients for M. pneumoniae (50% vs. 36.7%, 
p = 0.49). Other characteristics of the patients are presented 
in the Table 1, which shows no significant difference on clin-
ical manifestations between these two groups.
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Para-clinical findings
Complete blood cell count was similar in the two groups of 
positive and negative PCR for M. pneumoniae. Patients 
with positive PCR for M. pneumoniae had a mean white 
blood cells (WBC) count of 10,200/m3 with 65% polymor-
phonuclear cells (PMN), whilst mean WBC in the PCR-neg-
ative cases was 10,000/m3 with 54% PMN. Expert radiologist 
reports of chest X-ray were available for 70 patients; among 
PCR-positive patients for M. pneumoniae there were 2 cases 
of lobar infiltrations and 3 of interstitial infiltrations. Posi-
tive radiological findings among PCR-positive patients for 
M. pneumoniae was 71.4% (5 of 7), lower than the 77.8% (49 
of 63) found among PCR-negative patients, but this differ-
ence was not significant (p = 0.66).
DISCUSSION
Respiratory infections with M. pneumoniae are common in 
most areas of the world, which cause atypical pneumonia 
and other respiratory tract diseases with outbreaks occur-
ring every 4-7 year intervals. The annual rate of infection 
is estimated between 1.3% in endemic periods and 50% in 
epidemic periods. About 15-20% of community-acquired 
pneumonia was associated with M. pneumoniae, with an in-
cidence of 2 cases per 1,000 population annually.25,26
The role of M. pneumoniae in respiratory infections was 
investigated in different regions, but its prevalence varies 
greatly from study to study. Although geographical regions 
can alter the prevalence of M. pneumoniae in respiratory in-
fections, type of study, age of studied patients and the meth-
ods used for detecting M. pneumoniae can be responsible 
for the discrepant results of previous studies. Our study re-
vealed that 10% of patients with LRTIs could be attributed 
to this atypical bacteria, which is similar to that one reported 
in other parts of Asia,27,28 in spite of the fact that our study 
was conducted in a different location and at a different time. 
Ngeow et al. carried on a large surveillance study in Asia, 
which showed the prevalence of M. pneumoniae in about 
12% among children with community-acquired pneumo-
nia.27 In an earlier study from South-eastern Asia, Ouchi 
et al. studied 1,104 Japanese children with acute LRTIs and 
found M. pneumoniae in 13% of the patients,28 also in agree-
ment with our study. 
Low frequency of M. pneumoniae was reported in only 
few studies, such as the study by Elkholy et al. involving 111 
Egyptian children with positivity rate of only 4.5%29 and the 
study by Meijer et al. on 557 Dutch patients with positiv-
ity rate of only 1.3%.30 However, there are several studies re-
porting higher frequency of M. pneumoniae. In the study by 
Principi et al. on 613 Italian children from 21 different cent-
ers, who were hospitalized because of community acquired 
LRTIs, this pathogen was found in 34% of the patients.31 In 
the study by Liu et al. on 256 Taiwanese patients with clini-
cal suspicion of atypical pneumonia, M. pneumoniae was 
positive in 32% of the cases.24 In another study by Maltezou 
et al. on 65 Greek children, M. pneumoniae infection was 
confirmed in 27.5% of them.32 As expected, the frequency of 
M. pneumoniae pneumonia should be much higher at the 
time of outbreaks. The study by Kim et al. in Seoul, Korea, on 
234 hospitalized children with community-acquired LRTIs 
during two outbreaks revealed about 65% of patients with 
M. pneumoniae pneumonia.33 
Table 1. Characteristics of patients with acute lower respiratory tract infections
Characteristics PCR-Positive for M. pneumoniae PCR-Negative for M. pneumoniae p-value 
 (n = 10)  (n = 90) *
Gender (male/female) 5/5 59/31 0.49
Cough 10 (100%) 90 (100%) -
Fever 8 (80%) 57 (63.3%) 0.49
Flu like symptoms 4 (40%) 57 (63.3%) 0.18
Dyspnea 5 (50%) 33 (36.7%) 0.49
Pulmonary rales 3 (30%) 34 (37.8%) 0.74
Wheezing 1 (10%) 23 (25.6%) 0.68
Conjunctivitis 2 (20%) 11 (12.2%) 0.34
Hospitalized cases 6 (60%) 56 (62.2%) 0.57
Outpatient cases 4 (40%) 34 (37.8%) 0.57
*Not significant in all these comparisons.
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However, it should be emphasized that some of these 
studies reflect the prevalence of M. pneumoniae in hospital-
ized patients, while we also included outpatients, albeit with 
similar frequency with hospitalized cases. Although the 
study by Sidal et al. in Istanbul, Turkey on 284 patients, seen 
at an outpatient clinic with respiratory symptoms, showed 
positive antibody for M. pneumoniae in about 30% of cases.34 
Another study by Butun et al. in Izmir, Turkey on 100 chil-
dren, receiving care at the outpatient department with res-
piratory symptoms, revealed positive antibody for M. pneu-
moniae in only 8% of cases.35
In our study, the M. pneumoniae in autumn season was 
found higher compared to other seasons, which contrasts 
with the Turkish study indicating significantly higher fre-
quency of this pathogen in winter season.34 Meanwhile in 
the study by Foy et al. in Seattle during an 11-year period, no 
significant seasonal variation was documented. 36
Atypical pneumonia could be distinguished from other 
types of pneumonias by its mild clinical course and its ability 
to cause different symptoms in different people. Cough and 
throat pain are common symptoms, whilst fever is usually a 
symptom of hospitalized patients diagnosed with pneumo-
nia. However, we did not find any specific clinical character-
istic that could accurately identify patients with M. pneumo-
niae, similarly to other studies.35,37 In fact, none of the signs 
and symptoms was unique to M. pneumoniae infections ena-
bling to predict atypical pathogens based on clinical charac-
teristics. Such findings can emphasize the point that clinical 
and laboratory features alone cannot predict the etiology of 
community-acquired pneumonia in children and therefore 
are not useful in therapeutic decision-making.38,39 It shows 
the importance of effective laboratory diagnosis tools to de-
tect such pathogens. As clinical symptoms are nonspecific, 
persistent cough lasting more than a week, refractory to 
conventional antibiotic therapy should prompt clinicians 
to suspect the diagnosis of LRTIs by atypical microorgan-
isms.40 However, initiation of effective antibiotic therapy is 
usually delayed. Such delay may lead to some complications, 
while the patients are not appropriately treated.31
Therefore, detection of microorganisms and appropriate 
treatments are the key points in the management of patients 
with LRTIs. Although M. pneumoniae can be isolated from 
cultures, this is a difficult and time-consuming method which 
limits its clinical usefulness. Therefore, the PCR method for 
detecting M. pneumoniae in throat swabs could be considered 
as the most practical method for rapid diagnosis, particularly 
in younger children and in early stage of disease.20,24
M. pneumoniae is an atypical bacterium that could 
cause LRTIs worldwide, which requires adding a macrolide 
in the antibiotic regimen.40 Prompt diagnosis by appropri-
ate technique and starting appropriate antibiotic therapy 
could prevent the use of unnecessary antibiotics and fur-
ther complications.
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